Skip to main content
. Author manuscript; available in PMC: 2016 Oct 13.
Published in final edited form as: Br J Haematol. 2016 Aug 1;175(2):226–236. doi: 10.1111/bjh.14254

Fig 1.

Fig 1

Kaplan–Meier survival plots of AML patients with pre-treatment DNMT3A R882 mutations who cleared DNMT3A R882 mutation at complete remission (CR) and those who did not. (A) Disease-free survival. (B) Overall survival. (C) Disease-free survival for patients with remission samples collected within 30 d of morphological CR date. (D) Overall survival for patients with remission samples collected within 30 d of morphological CR date. Group 1 includes patients whose DNMT3A R882 mutations cleared below the variant allele frequency (VAF) cut-off of 3% in their remission sample and who had no other AML mutation. Group 2 includes patients with a DNMT3A R882 mutation with a VAF ≥3% in their remission sample with or without other AML mutations.